Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other pharma ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other pharma ...

Novo Nordisk A/S (NYSE:NVO)’s 2024 free cash flow fell to DKK 71.8 billion from DKK 75.6 billion in 2023, driven by higher capital spending of DKK 31.1 billion, up from DKK 16.4 billion.

Novo Nordisk, for its part, is expected to jump from 10th place to sixth this year, according to Evaluate Pharma’s consensus forecasts. Nevertheless, it’s Roche that’s been tipped to stand ...

So, despite its recent dip, Novo Nordisk remains an excellent pharmaceutical stock to buy and hold. AstraZeneca's strategy is different from Novo Nordisk's. Whereas the latter derives most of its ...